Philip D. Leming

19.0k total citations · 2 hit papers
21 papers, 1.9k citations indexed

About

Philip D. Leming is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Philip D. Leming has authored 21 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Philip D. Leming's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (5 papers) and Immunotherapy and Immune Responses (3 papers). Philip D. Leming is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (5 papers) and Immunotherapy and Immune Responses (3 papers). Philip D. Leming collaborates with scholars based in United States and Germany. Philip D. Leming's co-authors include David C. Smith, John D. Powderly, John M. Kirkwood, F. Stephen Hodi, Scott Antonia, Julie R. Brahmer, Scott Gettinger, David R. Spigel, David F. McDermott and Leora Horn and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Philip D. Leming

21 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

2018 539 citations Scott Gettinger, Leora Horn et al. Journal of Clinical Oncology profile →
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

2019 409 citations Suzanne L. Topalian, F. Stephen Hodi et al. JAMA Oncology profile →

Peers

Countries citing papers authored by Philip D. Leming

Since Specialization

Citations

This map shows the geographic impact of Philip D. Leming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip D. Leming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip D. Leming more than expected).

Fields of papers citing papers by Philip D. Leming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip D. Leming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip D. Leming. The network helps show where Philip D. Leming may publish in the future.

Co-authorship network of co-authors of Philip D. Leming

This figure shows the co-authorship network connecting the top 25 collaborators of Philip D. Leming. A scholar is included among the top collaborators of Philip D. Leming based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip D. Leming. Philip D. Leming is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab breakdown → 2019 ·JAMA Oncology ·Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Alexander Drilon, Jedd D. Wolchok, Richard D. Carvajal, M. Brent McHenry, Fareeda Hosein, Christopher Harbison, Joseph F. Grosso, Mario Sznol	409
2	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study breakdown → 2018 ·Journal of Clinical Oncology ·Scott Gettinger, Leora Horn, David M. Jackman, David R. Spigel, Scott Antonia, Matthew D. Hellmann, John D. Powderly, Rebecca S. Heist, Lecia V. Sequist, David C. Smith, Philip D. Leming, William J. Geese, (unknown), Ang Li, Julie R. Brahmer	539
3	Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors 2017 ·Cancer Research ·Julie R. Brahmer, Leora Horn, David M. Jackman, David R. Spigel, Scott Antonia, Matthew D. Hellmann, John D. Powderly, Rebecca S. Heist, Lecia V. Sequist, David C. Smith, Philip D. Leming, William J. Geese, (unknown), Ang Li, Scott Gettinger	41
4	Multivariate prognostic factors in metastatic uveal melanoma (UM). 2015 ·Journal of Clinical Oncology ·(unknown), Nagla Abdel Karim, Philip D. Leming, (unknown), (unknown), Changchun Xie, (unknown), Zélia M. Corrêa, James J. Augsburger	1
5	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma 2014 ·JAMA ·F. Stephen Hodi, Charles Lee, David F. McDermott, Uma N. M. Rao, Lisa H. Butterfield, Ahmad A. Tarhini, Philip D. Leming, Igor Puzanov, Donghoon Shin, John M. Kirkwood	273
6	Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. 2014 ·Journal of Clinical Oncology ·F. Stephen Hodi, Mario Sznol, Harriet M. Kluger, David F. McDermott, Richard D. Carvajal, Donald P. Lawrence, Suzanne L. Topalian, Michael B. Atkins, John D. Powderly, William H. Sharfman, Igor Puzanov, David C. Smith, Philip D. Leming, Evan J. Lipson, Janis M. Taube, Robert A. Anders, Christine E. Horak, Georgia Kollia, Ashok Gupta, Jeffrey A. Sosman	100
7	Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, D. M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, Suzanne L. Topalian, F. Stephen Hodi, Mario Sznol, Christopher Harbison, Georgia Kollia, Julie R. Brahmer	15
8	Long-Term Survival of Ipilimumab-Naïve Patients (Pts) with Advanced Melanoma (Mel) Treated with Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in a Phase 1 Trial 2014 ·Annals of Oncology ·David F. McDermott, Harriet M. Kluger, Mario Sznol, Richard D. Carvajal, Donald P. Lawrence, Suzanne L. Topalian, M.B. Atkins, John D. Powderly, William H. Sharfman, Igor Puzanov, David C. Smith, Philip D. Leming, Evan J. Lipson, Janis M. Taube, Robert A. Anders, Christine E. Horak, Georgia Kollia, Jeffrey A. Sosman, F. Stephen Hodi	6
9	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. 2014 ·Journal of Clinical Oncology ·Julie R. Brahmer, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, Suzanne L. Topalian, F. Stephen Hodi, Mario Sznol, Christopher Harbison, Georgia Kollia, Ashok Gupta, Scott Gettinger	65
10	A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602) 2013 ·Clinical Cancer Research ·Craig L. Slingluff, Charles Lee, Fengmin Zhao, Kimberly A. Chianese‐Bullock, Walter C. Olson, Lisa H. Butterfield, Theresa L. Whiteside, Philip D. Leming, John M. Kirkwood	90
11	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. 2013 ·Journal of Clinical Oncology ·F. Stephen Hodi, Sandra J. Lee, David F. McDermott, Uma N. M. Rao, Lisa H. Butterfield, Ahmad A. Tarhini, Philip D. Leming, Igor Puzanov, John M. Kirkwood, (unknown)	20
12	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma 2012 ·Journal of Clinical Oncology ·Keith T. Flaherty, Sandra J. Lee, Fengmin Zhao, Lynn M. Schuchter, Lawrence E. Flaherty, Richard Kefford, Michael B. Atkins, Philip D. Leming, John M. Kirkwood	160
13	Inferior vena cava filters in the management of cancer-associated venous thromboembolism: a systematic review 2011 ·SHILAP Revista de lepidopterología ·R. Ganapathi Raman, Philip D. Leming, Manish Bhandari, Daniel Long, Michael B. Streiff	1
14	Inferior vena cava filters in the management of cancer-associated venous thromboembolism: a systematic review 2010 ·Oncology Reviews ·R. Ganapathi Raman, Philip D. Leming, Manish Bhandari, (unknown), Michael B. Streiff	2
15	Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. 2010 ·Journal of Clinical Oncology ·K. T. Flaherty, (unknown), Lynn M. Schuchter, Lawrence E. Flaherty, James R. Wright, Philip D. Leming, John M. Kirkwood	45
16	Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer 1994 ·Cancer Chemotherapy and Pharmacology ·Elizabeth Poplin, Patricia LoRusso, Jacob J. Lokich, John J. Gullo, Philip D. Leming, Joseph J. Schulz, (unknown), William McCulloch, Laurence H. Baker, Philip S. Schein	34
17	Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer 1994 ·Cancer Chemotherapy and Pharmacology ·Elizabeth Poplin, Patricia LoRusso, Jacob J. Lokich, John J. Gullo, Philip D. Leming, Joseph J. Schulz, (unknown), William McCulloch, (unknown), Philip S. Schein	4
18	Nonspecific Corticosteroid Therapy in Patients Receiving Intra-arterial Chemotherapy for Hepatic Metastases of Colorectal Origin 1988 ·Cancer Investigation ·(unknown), Philip D. Leming, (unknown)	1
19	Atypical herpes simplex (HSV) infection in a patient with Hodgkin's disease 1984 ·Cancer ·Philip D. Leming, Sue Ellen Martin, Leonard A. Zwelling	21
20	Magnesium Carbonate Pica: An Unusual Case of Iron Deficiency 1981 ·Annals of Internal Medicine ·Philip D. Leming, (unknown), (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact